Bazedoxifene Acetate
FDA-approved product (tablet, oral).
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Postmenopausal osteoporosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Selective estrogen receptor modulators
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis61.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Bazedoxifene Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene
NCT00847821 · start 2009-05
Registered record
- Registry ID
- NCT00847821
- Conditions
- Postmenopause
- Interventions
- Bazedoxifene 10 mg/CE 0.625 mg; Bazedoxifene 20 mg/CE 0.625 mg; Bazedoxifene 40 mg/CE 0.625 mg; Bazedoxifene 10 mg/CE 0.45 mg; Bazedoxifene 20 mg/CE 0.45 mg; Bazedoxifene 40 mg/CE 0.45 mg; Raloxifene 60 mg; Placebo
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Terminated
- Start
- 2009-05
- Completion
- 2010-08
- Enrolment
- 185
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostmenopauseInterventionBazedoxifene 10 mg/CE 0.625 mg; Bazedoxifene 20 mg/CE 0.625 mg; Bazedoxifene 40 mg/CE 0.625 mg; Bazedoxifene 10 mg/CE 0.45 mg +4 morePhaseNot recordedRegistry statusTerminatedStudy Evaluating Changes In Mammographic Breast Density
NCT00774267 · start 2009-01
Registered record
- Registry ID
- NCT00774267
- Conditions
- Osteoporosis
- Interventions
- BZA 20 mg/CE 0.45 mg; BZA 20 mg/CE 0.625 mg; Raloxifene 60 mg; Placebo
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2009-01
- Completion
- 2010-04
- Enrolment
- 507
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteoporosisInterventionBZA 20 mg/CE 0.45 mg; BZA 20 mg/CE 0.625 mg; Raloxifene 60 mg; PlaceboPhaseNot recordedRegistry statusCompletedStudy Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
NCT00808132 · start 2009-01
Registered record
- Registry ID
- NCT00808132
- Conditions
- Menopause; Osteoporosis
- Interventions
- bazedoxifene 20 mg/ conjugated estrogens 0.45 mg; bazedoxifene 20 mg/ conjugated estrogens 0.625 mg; bazedoxifene 20 mg; conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-01
- Completion
- 2011-02
- Enrolment
- 1,886
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMenopause; OsteoporosisInterventionbazedoxifene 20 mg/ conjugated estrogens 0.45 mg; bazedoxifene 20 mg/ conjugated estrogens 0.625 mg; bazedoxifene 20 mg; conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg +1 morePhasePhase 3Registry statusCompletedStudy Evaluating Premarin and Bazedoxifene Potential Interaction
NCT00745173 · start 2008-09
Registered record
- Registry ID
- NCT00745173
- Conditions
- Postmenopause
- Interventions
- Premarin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-09
- Completion
- 2008-10
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostmenopauseInterventionPremarinPhasePhase 1Registry statusCompletedStudy Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women
NCT00706225 · start 2008-06
Registered record
- Registry ID
- NCT00706225
- Conditions
- Postmenopause
- Interventions
- Bazedoxifene and conjugated estrogens
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-06
- Completion
- 2008-07
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostmenopauseInterventionBazedoxifene and conjugated estrogensPhasePhase 1Registry statusCompletedStudy Comparing Formulations of Bazedoxifene/Conjugated Estrogens
NCT00550303 · start 2007-10
Registered record
- Registry ID
- NCT00550303
- Conditions
- Healthy
- Interventions
- bazedoxifene/conjugated estrogens combination
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-10
- Completion
- 2007-11
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionbazedoxifene/conjugated estrogens combinationPhasePhase 1Registry statusCompletedStudy Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms
NCT00479778 · start 2007-04
Registered record
- Registry ID
- NCT00479778
- Conditions
- Postmenopause
- Interventions
- Bazedoxifene/conjugated estrogens
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-04
- Completion
- 2007-07
- Enrolment
- 72
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostmenopauseInterventionBazedoxifene/conjugated estrogensPhasePhase 1Registry statusCompletedStudy Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women
NCT00464789 · start 2007-03
Registered record
- Registry ID
- NCT00464789
- Conditions
- Menopause
- Interventions
- Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-03
- Completion
- 2007-05
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMenopauseInterventionBazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tabletPhasePhase 1Registry statusCompletedStudy Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women
NCT00465075 · start 2007-03
Registered record
- Registry ID
- NCT00465075
- Conditions
- Healthy
- Interventions
- Bazedoxifene/conjugated estrogens combination
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-03
- Completion
- 2007-04
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionBazedoxifene/conjugated estrogens combinationPhasePhase 1Registry statusCompletedBioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women
NCT00396799 · start 2006-11
Registered record
- Registry ID
- NCT00396799
- Conditions
- Menopause
- Interventions
- bazedoxifene/conjugated estrogens
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-11
- Completion
- 2006-11
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMenopauseInterventionbazedoxifene/conjugated estrogensPhasePhase 1Registry statusCompletedEffect of Bazedoxifene, Raloxifene, and Placebo on Breast Density
NCT00418236 · start 2006-10
Registered record
- Registry ID
- NCT00418236
- Conditions
- Breast Cancer
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2006-10
- Completion
- 2010-04
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionNot recordedPhaseNot recordedRegistry statusCompletedStudy Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution
NCT00367536 · start 2006-08
Registered record
- Registry ID
- NCT00367536
- Conditions
- Postmenopause
- Interventions
- bazedoxifene/conjugated estrogens combination tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-08
- Completion
- 2006-08
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostmenopauseInterventionbazedoxifene/conjugated estrogens combination tabletPhasePhase 1Registry statusCompletedStudy Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women
NCT00384072 · start 2006-05
Registered record
- Registry ID
- NCT00384072
- Conditions
- Postmenopause; Osteoporosis
- Interventions
- bazedoxifene BZA-20
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-05
- Completion
- 2007-09
- Enrolment
- 500
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostmenopause; OsteoporosisInterventionbazedoxifene BZA-20PhasePhase 3Registry statusCompletedStudy Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause
NCT00234819 · start 2005-10
Registered record
- Registry ID
- NCT00234819
- Conditions
- Vasomotor Symptoms Associated With Menopause
- Interventions
- Bazedoxifene/Conjugated Estrogen
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-10
- Completion
- 2007-02
- Enrolment
- 325
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVasomotor Symptoms Associated With MenopauseInterventionBazedoxifene/Conjugated EstrogenPhasePhase 3Registry statusCompletedStudy Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause
NCT00238732 · start 2005-10
Registered record
- Registry ID
- NCT00238732
- Conditions
- Vaginal Atrophy
- Interventions
- Bazedoxifene/Conjugated Estrogen
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-10
- Completion
- 2007-03
- Enrolment
- 650
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVaginal AtrophyInterventionBazedoxifene/Conjugated EstrogenPhasePhase 3Registry statusCompleted